We have presented the study to the federal government, to the chief negotiator. We've had good access in terms of presenting our issues.
The costs are a major element of these proposals, particularly, as you said, with provincial governments, but also with large payers. We noted in our comments that the Canadian Life and Health Insurance Association, which represents large employers and insurance companies, and a number of other groups have expressed concern.
The federal government has listened to us and has indicated that it appreciates the study very much. The government has not committed to move toward what the Europeans want. It's listening. It's trying to gauge what the impact will be, but the extra cost, the cost of not being able to get generics for an extra three and a half years, is clearly a critical element on the table.